CDK18 and acute myeloid leukemia: At the same time, MAP4K1, G6PD, CDK18, SOCS1, ETS2, and AKR1B1 showed opposite trends (Supplementary Figures S2C,S2F), suggesting that KDM5B and SMURF2 might be protective factors for AML patients.